Direct answer. Autoimmune hepatitis is an immune-related liver disease. It can cause inflammation and damage while a person feels well. Diagnosis combines the history, blood tests and other investigations; no single test establishes it. Treatment and monitoring aim to control liver inflammation, while remission does not mean treatment can be stopped without clinical supervision. Definition; Diagnostic original.
- Autoimmune hepatitis is distinct from viral hepatitis and is not diagnosed from symptoms alone.
- A positive autoantibody or raised liver enzyme needs interpretation with the full clinical picture.
- Treatment, remission and relapse are different care questions.
- Immunosuppressive medicines require safety monitoring and coordinated review.
- New jaundice, bleeding or severe illness needs assessment rather than routine reassurance.
- Nutrition and prescribed deficiency prevention are separate from unproven immune-boosting remedies.
Table of contents
- Evidence summary
- What autoimmune hepatitis is and what it can affect
- Immune injury, uncertain triggers and medicine-related mimics
- Treatment, remission and relapse: separate clinical goals
- Diet, bone protection and unproven immune remedies
- Diagnosis: enzymes, autoantibodies, imaging and biopsy
- Jaundice, bleeding and severe-illness warning signs
- Immunosuppression, adverse effects and medicine interactions
- Pregnancy, children and coexisting conditions
- Appointments, treatment records and supervised changes
- Immune mechanisms versus proven human treatment
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Question | Evidence role | Interpretation / confidence |
|---|---|---|
| Does hepatitis always mean a viral infection? | Disease distinction | No. Autoimmune hepatitis concerns an immune attack on the liver. |
| Can one blood test establish the diagnosis? | Combined diagnostic original | No. The history, other results and often tissue assessment matter. |
| Does feeling well exclude liver inflammation? | Symptom limitations | No. Disease may be found before noticeable symptoms. |
| Does remission permit self-stopping treatment? | Relapse and monitoring context | No. Treatment changes and withdrawal require clinical supervision. |
| Do medicines need safety checks? | Selected monitoring context | Yes. The actual product, other medicines and clinical findings shape the plan. |
| Is a special diet an established cure? | Nutrition evidence boundary | No dietary cure or independent supplement replacement is established here. |
Confidence is moderate in the disease distinctions, combined diagnostic roles and monitoring principles. Care statements are attributed clinical context, not a newly conducted systematic review or financially cleared numerical treatment ranking. Dated patient and medicine sources do not supply a complete current drug menu. No independently verified supplement replacement was established.
What autoimmune hepatitis is and what it can affect
Autoimmune hepatitis involves immune activity directed against the liver. It is distinct from a viral infection such as hepatitis B or C. The shared word “hepatitis” describes liver inflammation; it does not establish the cause or select treatment. Definition and distinction.
The NIDDK source describes type1 and type2 patterns and possible overlap with bile-duct disease, including primary biliary cholangitis or primary sclerosing cholangitis. Those labels concern a clinical assessment, not categories a reader can assign from age or a positive antibody alone. Ask whether the report describes one disease, an overlap or an unresolved question. Types and overlap context.
Possible complications include scarring and liver failure. Some people first come to attention with advanced liver findings; others are investigated earlier. The diagnosis name does not supply an individual stage. Ask what evidence shows current inflammation, existing damage and any separate bile-duct problem. Complication context.
Immune injury, uncertain triggers and medicine-related mimics
The exact cause is uncertain. The NIDDK source describes a possible combination of genetic susceptibility and environmental triggers. It does not establish that a person caused the disease through one food, stressor or infection. A proposed immune mechanism is different from identifying the cause in an individual. Cause uncertainty.
Symptoms may include tiredness, joint pain, poor appetite, abdominal discomfort or jaundice, but some people have no symptoms. These findings are not specific to autoimmune hepatitis. A new symptom should be assessed in its own context rather than automatically labelled a flare. Symptoms and absence of symptoms.
Medicine-related liver injury can resemble autoimmune hepatitis. The source therefore emphasizes sharing all medicines and herbal products with the clinician. That distinction can change the investigation and follow-up; it is not a self-diagnosis or instruction to stop a prescription on suspicion. Medicine-related mimic.
A useful history includes earlier liver results, other autoimmune conditions, medication changes and the timing of symptoms. Bring what is known and describe uncertainty honestly. The team needs an accurate sequence rather than a forced explanation that attributes every finding to one trigger.
Treatment, remission and relapse: separate clinical goals
The dated NIDDK framework describes medicines that reduce immune activity, including corticosteroids and immunosuppressants. Their purpose is to control liver inflammation. The actual choice depends on disease and safety findings; this guide does not reproduce a dose, taper or complete current first-line menu. Bounded treatment-purpose context.
Remission concerns an improved disease state, while relapse means disease activity returns. Treatment withdrawal requires supervision because liver injury can recur. A person who feels better should ask how the team evaluates control and what ongoing checks are needed. Remission, relapse and supervised withdrawal.
If response is incomplete or adverse effects interfere with care, the specialist reviews the plan. Clinical guidance explaining that process is not a financially cleared comparison proving one medicine superior. No response percentage, guaranteed cure or universal duration is supplied here. Ask what improvement is expected and what would change the recommendation.
Azathioprine is one prescription immunosuppressant discussed in the sources. NHS education describes blood tests before and during its use to look for liver, kidney or bone-marrow problems. That monitoring role does not establish that every person should receive the same medicine or timetable. Dated medicine-purpose and monitoring original.
Diet, bone protection and unproven immune remedies
The NIDDK nutrition source does not identify diet as a cause or prevention strategy for autoimmune hepatitis. It supports balanced nutrition. A diet marketed as autoimmune healing has not thereby demonstrated durable control of liver inflammation. Nutrition evidence boundary.
Long-term corticosteroid use can affect bone density. The source describes clinician-directed calcium and vitaminD supplementation in that context. Treating a documented nutritional or bone-health need is different from replacing immune treatment with a supplement. Ask which assessment supports supplementation and how the exact product fits the medicine plan. Bone-protection context.
No independently verified herbal, probiotic or immune-boosting replacement was established in this source set. Bring ingredients and packaging to the clinician or pharmacist. The NHS interaction source says there is insufficient information to declare complementary products safe with azathioprine. A natural label does not settle interactions. Supplement uncertainty.
Tell the team about poor intake, weight change, mood concerns, sleep disruption or difficulty attending appointments. Practical support can improve the usability of a care plan without requiring an unsupported promise that lifestyle changes alone treat the underlying immune injury.
Diagnosis: enzymes, autoantibodies, imaging and biopsy
Diagnosis combines the medical history, examination and tests. Blood work can assess liver enzymes, autoantibodies and immunoglobulinG, while other tests investigate alternative liver diseases. No single autoantibody or enzyme value establishes autoimmune hepatitis. Combined blood-test purposes.
Imaging and liver biopsy can answer different questions. The NIDDK source describes looking at structure and obtaining tissue to assess disease features and damage. An imaging report and a tissue report are not interchangeable results. Ask what the proposed investigation adds and whether it could change management. Imaging and tissue-assessment roles.
A positive autoimmune test needs interpretation with the other findings. Similarly, an abnormal liver enzyme does not name the cause by itself. Bring prior reports to the appointment so the clinician can distinguish a long-standing finding from a new change. Request an explanation of what is established and what remains uncertain.
Before a biopsy or other procedure, ask about its purpose, risks, medicine instructions and how results will be communicated. This guide supplies no home diagnostic score, numerical threshold or procedure preparation protocol. The individual consent discussion belongs with the treating team.
Jaundice, bleeding and severe-illness warning signs
New or unexplained yellow eyes or skin need urgent assessment. Jaundice guidance. Vomiting blood with faintness, confusion, black stools or feeling seriously unwell needs emergency care. Bleeding warning signs. A previously diagnosed liver disease is not a reason to wait with a new alarm.
Poor intake with reduced urination or persistent dizziness needs prompt help. Confusion or difficulty waking is an emergency warning sign. Dehydration and severe-illness guidance. Use local emergency services outside the UK rather than waiting for a routine specialist contact.
For someone taking azathioprine, the dated NHS safety source identifies infection symptoms, unusual bruising or bleeding, and severe abdominal symptoms as reasons for urgent professional advice. Severe allergic breathing or swelling symptoms need emergency care. Follow the prescribed urgent-response plan rather than inventing a restart or withdrawal regimen. Selected serious medicine warnings.
Immunosuppression, adverse effects and medicine interactions
Before immune treatment, ask whether hepatitis B screening and a reactivation-prevention plan are needed; current or past infection can reactivate with immunosuppression. Hepatitis B screening and reactivation context.
Immune treatment can create safety issues separate from the liver condition. Ask which blood checks, infection precautions and symptom contacts apply to the actual medicine. More than one service may prescribe treatment; one accurate list helps them coordinate changes. Selected monitoring and infection context.
The NHS azathioprine interaction page names allopurinol, other immunosuppressants, warfarin and chemotherapy among medicines requiring disclosure. It also describes live-vaccine and procedure precautions. These examples are not a complete interaction checker and do not permit a reader to combine or adjust treatments independently. Exact-product interaction review.
Before vaccination or surgery, state that you take immune treatment and give the medicine name. Vaccine type and the individual treatment plan matter. Ask the responsible clinician to supply instructions; a broad recommendation to keep vaccinations up to date does not make every live vaccine suitable.
If another clinician changes a prescription, share that information with the hepatitis team and pharmacist. Include nonprescription painkillers, herbal blends and vitamins. The practical goal is a coordinated plan, not a blanket claim that all medicines are unsafe or that familiar products need no review.
Pregnancy, children and coexisting conditions
Pregnancy planning and breastfeeding deserve a review of the actual disease and medicines. The dated NHS azathioprine source emphasizes discussion and avoiding unsupervised stopping; it does not provide personal clearance for every product, dose or infant circumstance. Tell the maternity and liver teams about current treatment. Dated pregnancy and feeding context.
Autoimmune hepatitis can occur in adults or children, and other autoimmune or bile-duct conditions can overlap. The NIDDK definition source describes that range. A typical age, sex or antibody pattern is not a safety gate for investigation. A child requires an appropriate paediatric plan. Population and overlap distinctions.
Existing cirrhosis, other infections and substantial coexisting illness may change assessment and treatment. Ask who coordinates the plan across specialties. This article supplies no universal exemption from monitoring, exercise clearance or personal treatment contraindication list.
Appointments, treatment records and supervised changes
Ask for a written plan stating the diagnosis, current findings, medicine names, monitoring arrangements and whom to contact about new symptoms. Check how results will be reviewed and what happens if a planned appointment or test is missed. A schedule is useful only when its purpose and contact route are clear.
Do not interpret remission as permission to stop treatment independently. The dated NIDDK source warns about unsupervised withdrawal. If access, cost or adverse effects make continuation difficult, contact the prescribing service before a gap occurs so the clinical issue can be reviewed. Supervision and withdrawal warning.
Keep a record of earlier tests and treatment changes, including why a medicine was changed and any previous reaction. If care transfers to another clinic, share those records. A single remembered enzyme result is less useful than the actual report and the team’s interpretation.
Discuss the practical effects of long-term care: travel, work, medication supply, blood tests and emotional strain. Request a plan that fits those circumstances. This guide supplies no personal dose or taper; the actual medicine instructions and changes come from the treating team.
Immune mechanisms versus proven human treatment
An immune marker or laboratory pathway does not establish that a supplement safely controls human liver disease. Animal and cell studies are excluded from the clinical-efficacy verdict. Human studies need meaningful disease and patient outcomes, adequate safety follow-up and a traceable original financial chain. No manufacturer-funded outcome claim is certified as financially independent here; attributed clinical guidance and a cleared comparative trial would be different evidence roles.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 15 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The illness has no corporate owner or manufacturing country. Pharmaceutical and vaccine manufacturers, diagnostic suppliers, care providers and supplement sellers can earn income around prevention, diagnosis and treatment. The source audit below separates institutional income, permitted gift routes, outside-reviewer interests and original treatment evidence. Unknown allocation remains unknown; an interest is not an allegation of improper conduct.
A funding tier measures proximity to the subject; a credibility grade reflects transparency and accuracy incentives. Tier4 producer or commercially supported efficacy is excluded from an independent benefit verdict even when a source is free. The separate2023 meeting declaration does not establish company funding or compensation for the March2023 NIDDK patient series. The infographic summarises these disclosed relationships; it does not invent proportions of a page budget.
| Source | Funding / backers | Country / jurisdiction | Independence / credibility / gaps | Role in this article |
|---|---|---|---|---|
| NIDDK autoimmune-hepatitis series, March2023; actual reviewer credit | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. The series credits Michele Tana, UCSF. Actual November2023 meeting disclosure lists Merck consultancy within its past24-month disclosure period. Amounts and exact dates unresolved; no payment or sponsorship of the March2023 patient page is inferred. | United States; NIDDK Bethesda, Maryland; credited reviewer University of California, San Francisco. Underlying trial and manufacturer jurisdictions not fully traced. | Tier 3 relevant commercially connected outside reviewer; public institution separately identified. C provisional — actual March2023 body/series credit read for bounded explanation and care roles. Public clinical review supports accuracy; dated treatment framework, outside interests and unclosed contemporary page/trial finance prevent an independent efficacy ranking. No numerical response rate, complete current drug menu, personal taper or stop rule adopted. | Series identity, date and credited outside reviewer |
| NIDDK autoimmune-hepatitis definition/facts, March2023 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. The series credits Michele Tana, UCSF. Actual November2023 meeting disclosure lists Merck consultancy within its past24-month disclosure period. Amounts and exact dates unresolved; no payment or sponsorship of the March2023 patient page is inferred. | United States; NIDDK Bethesda, Maryland; credited reviewer University of California, San Francisco. Underlying trial and manufacturer jurisdictions not fully traced. | Tier 3 relevant commercially connected outside reviewer; public institution separately identified. C provisional — actual March2023 body/series credit read for bounded explanation and care roles. Public clinical review supports accuracy; dated treatment framework, outside interests and unclosed contemporary page/trial finance prevent an independent efficacy ranking. No numerical response rate, complete current drug menu, personal taper or stop rule adopted. | Immune-related disease, overlap and complication distinctions |
| NIDDK autoimmune-hepatitis symptoms/causes, March2023 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. The series credits Michele Tana, UCSF. Actual November2023 meeting disclosure lists Merck consultancy within its past24-month disclosure period. Amounts and exact dates unresolved; no payment or sponsorship of the March2023 patient page is inferred. | United States; NIDDK Bethesda, Maryland; credited reviewer University of California, San Francisco. Underlying trial and manufacturer jurisdictions not fully traced. | Tier 3 relevant commercially connected outside reviewer; public institution separately identified. C provisional — actual March2023 body/series credit read for bounded explanation and care roles. Public clinical review supports accuracy; dated treatment framework, outside interests and unclosed contemporary page/trial finance prevent an independent efficacy ranking. No numerical response rate, complete current drug menu, personal taper or stop rule adopted. | Symptoms can be absent; causes uncertain and medicine-related mimics |
| NIDDK autoimmune-hepatitis diagnosis, March2023 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. The series credits Michele Tana, UCSF. Actual November2023 meeting disclosure lists Merck consultancy within its past24-month disclosure period. Amounts and exact dates unresolved; no payment or sponsorship of the March2023 patient page is inferred. | United States; NIDDK Bethesda, Maryland; credited reviewer University of California, San Francisco. Underlying trial and manufacturer jurisdictions not fully traced. | Tier 3 relevant commercially connected outside reviewer; public institution separately identified. C provisional — actual March2023 body/series credit read for bounded explanation and care roles. Public clinical review supports accuracy; dated treatment framework, outside interests and unclosed contemporary page/trial finance prevent an independent efficacy ranking. No numerical response rate, complete current drug menu, personal taper or stop rule adopted. | Combined assessment; blood, imaging and biopsy purposes |
| NIDDK autoimmune-hepatitis treatment, March2023 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. The series credits Michele Tana, UCSF. Actual November2023 meeting disclosure lists Merck consultancy within its past24-month disclosure period. Amounts and exact dates unresolved; no payment or sponsorship of the March2023 patient page is inferred. | United States; NIDDK Bethesda, Maryland; credited reviewer University of California, San Francisco. Underlying trial and manufacturer jurisdictions not fully traced. | Tier 3 relevant commercially connected outside reviewer; public institution separately identified. C provisional — actual March2023 body/series credit read for bounded explanation and care roles. Public clinical review supports accuracy; dated treatment framework, outside interests and unclosed contemporary page/trial finance prevent an independent efficacy ranking. No numerical response rate, complete current drug menu, personal taper or stop rule adopted. | Bounded treatment/remission/relapse roles; no personal taper or complete current menu |
| NIDDK autoimmune-hepatitis diet, March2023 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. The series credits Michele Tana, UCSF. Actual November2023 meeting disclosure lists Merck consultancy within its past24-month disclosure period. Amounts and exact dates unresolved; no payment or sponsorship of the March2023 patient page is inferred. | United States; NIDDK Bethesda, Maryland; credited reviewer University of California, San Francisco. Underlying trial and manufacturer jurisdictions not fully traced. | Tier 3 relevant commercially connected outside reviewer; public institution separately identified. C provisional — actual March2023 body/series credit read for bounded explanation and care roles. Public clinical review supports accuracy; dated treatment framework, outside interests and unclosed contemporary page/trial finance prevent an independent efficacy ranking. No numerical response rate, complete current drug menu, personal taper or stop rule adopted. | Balanced nutrition and clinician-led bone protection, not a dietary cure |
| NHS azathioprine purpose and monitoring, March9,2023; review overdue | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education; local medicine and vaccine rules can differ. | Tier 1 public medicine education provisional; complete contributor/original-trial finance unclassified. C provisional — actual March9,2023 body read; scheduled March2026 review overdue. Public safety/accountability incentive; dated simplification and unclosed financial chains. Selected medicine purpose, precautions and urgent warnings only; no current complete label, dose, broad pregnancy clearance or personal stopping algorithm. | Selected prescription, blood-monitoring, infection and vaccine context |
| NHS azathioprine adverse effects, March9,2023; review overdue | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education; local medicine and vaccine rules can differ. | Tier 1 public medicine education provisional; complete contributor/original-trial finance unclassified. C provisional — actual March9,2023 body read; scheduled March2026 review overdue. Public safety/accountability incentive; dated simplification and unclosed financial chains. Selected medicine purpose, precautions and urgent warnings only; no current complete label, dose, broad pregnancy clearance or personal stopping algorithm. | Selected serious reaction, infection, blood-count and organ warnings |
| NHS azathioprine interactions, March9,2023; review overdue | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education; local medicine and vaccine rules can differ. | Tier 1 public medicine education provisional; complete contributor/original-trial finance unclassified. C provisional — actual March9,2023 body read; scheduled March2026 review overdue. Public safety/accountability incentive; dated simplification and unclosed financial chains. Selected medicine purpose, precautions and urgent warnings only; no current complete label, dose, broad pregnancy clearance or personal stopping algorithm. | Specific medicine disclosure and live-vaccine precaution context |
| NHS azathioprine pregnancy/lactation, March9,2023; review overdue | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education; local medicine and vaccine rules can differ. | Tier 1 public medicine education provisional; complete contributor/original-trial finance unclassified. C provisional — actual March9,2023 body read; scheduled March2026 review overdue. Public safety/accountability incentive; dated simplification and unclosed financial chains. Selected medicine purpose, precautions and urgent warnings only; no current complete label, dose, broad pregnancy clearance or personal stopping algorithm. | Pregnancy/feeding team review; no broad individual safety clearance |
| NHS jaundice, January22,2024 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Urgent assessment of new or unexplained jaundice |
| NHS vomiting blood, August18,2025 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Bleeding emergency signs |
| NHS dehydration, May1,2026 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Poor intake and severe-illness warnings |
| NIDDK actual funding, gifts and location FAQ, May2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional provenance, not actual donor allocation |
| NIDDK budget/legislative index, May2024 review, newer requests listed | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Proposals distinguished from actual appropriations |
| NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate |
| NHS national website content and funding policy, October2022 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national England patient-information service. | Tier 3 editorial/funding self-disclosure. B provisional — explicit funding and disclosure policy actually read. Dated2022 policy, actual individual declarations and implementation not audited. | National website editorial/financial provenance |
| Actual AASLD November2023 faculty financial disclosure,32pages; selected Tana entry | Actual32-page AASLD The Liver Meeting2023 faculty disclosure, page13, lists Michele Tana as a Merck & Co., Inc. consultant. Introductory page defines past24-month company interests. Amounts, exact dates, society full backers and any NIDDK-page payment unclosed. | United States; AASLD meeting disclosure of UCSF clinician; company and original trial ownership/manufacturing chains unclosed. | Tier 3 relevant author-interest self-disclosure. B provisional for the actual stated dated relationship and disclosure window; no inference of patient-page funding, impropriety or full current financial clearance. Selected original declaration read, not a complete faculty-by-faculty audit. | Separate past24-month Merck consultancy; no patient-page payment inferred |
Frequently asked questions
Is autoimmune hepatitis contagious viral hepatitis?
It is a distinct immune-related liver disease; the cause of any concurrent infection needs its own assessment.
Does a positive antibody prove the diagnosis?
No. The history and combined investigations matter.
Can liver inflammation exist without symptoms?
Yes. Feeling well does not replace assessment of abnormal findings.
Can I stop medicines during remission?
No self-stopping rule is supplied. Discuss any change with the specialist and follow the monitoring plan.
Does calcium or vitaminD treat autoimmune hepatitis?
It may have a separate clinician-directed bone-health purpose; it is not a replacement for immune treatment.
Can an immune-boosting supplement replace care?
No independently verified replacement was established, and exact products require interaction review.
Sources and funding notes
- NIDDK autoimmune-hepatitis series, March2023; actual reviewer credit — Series identity, date and credited outside reviewer.
- NIDDK autoimmune-hepatitis definition/facts, March2023 — Immune-related disease, overlap and complication distinctions.
- NIDDK autoimmune-hepatitis symptoms/causes, March2023 — Symptoms can be absent; causes uncertain and medicine-related mimics.
- NIDDK autoimmune-hepatitis diagnosis, March2023 — Combined assessment; blood, imaging and biopsy purposes.
- NIDDK autoimmune-hepatitis treatment, March2023 — Bounded treatment/remission/relapse roles; no personal taper or complete current menu.
- NIDDK autoimmune-hepatitis diet, March2023 — Balanced nutrition and clinician-led bone protection, not a dietary cure.
- NHS azathioprine purpose and monitoring, March9,2023; review overdue — Selected prescription, blood-monitoring, infection and vaccine context.
- NHS azathioprine adverse effects, March9,2023; review overdue — Selected serious reaction, infection, blood-count and organ warnings.
- NHS azathioprine interactions, March9,2023; review overdue — Specific medicine disclosure and live-vaccine precaution context.
- NHS azathioprine pregnancy/lactation, March9,2023; review overdue — Pregnancy/feeding team review; no broad individual safety clearance.
- NHS jaundice, January22,2024 — Urgent assessment of new or unexplained jaundice.
- NHS vomiting blood, August18,2025 — Bleeding emergency signs.
- NHS dehydration, May1,2026 — Poor intake and severe-illness warnings.
- NIDDK actual funding, gifts and location FAQ, May2024 — Institutional provenance, not actual donor allocation.
- NIDDK budget/legislative index, May2024 review, newer requests listed — Proposals distinguished from actual appropriations.
- NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table — Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate.
- NHS national website content and funding policy, October2022 — National website editorial/financial provenance.
- Actual AASLD November2023 faculty financial disclosure,32pages; selected Tana entry — Separate past24-month Merck consultancy; no patient-page payment inferred.
Actual March2023 NIDDK bodies and series credit, actual selected November2023 original faculty disclosure, March2023 NHS medicine bodies and selected dated/current urgent-care sources were read. The older treatment framework and overdue NHS medicine reviews remain explicit. Fixed remission/withdrawal duration, numerical response rates, broad pregnancy safety, exact drug menus, taper schedules and universal live-vaccine instructions are excluded. The Merck consultancy is a separate declared relationship, not proof of sponsorship or payment for the NIDDK page. Complete contemporary reviewer compensation and original treatment-trial finance remain unresolved. Current primary patient guidance and the selected financial originals were read. Complete original treatment trials, their suppliers, society ownership/backer chains and contemporaneous page-review compensation were not audited. No personal dose, brand hierarchy or trial benefit percentage is supplied. ClinicalTrials.gov listings, institutional names and accreditation do not themselves establish safety or independence.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.